IC
CLDX icon

Ikarian Capital’s Celldex Therapeutics CLDX Stock Holding History

Ikarian Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6M Buy
+461,247
New +$12.6M 1.19% 21
2023
Q2 		– Sell
-106,057
Closed -$3.82M – 142
2023
Q1 		$3.82M Sell
106,057
-161,419
-60% -$6.97M 0.87% 43
2022
Q4 		$11.9M Sell
267,476
-50,000
-16% -$1.79M 2.88% 6
2022
Q3 		$8.92M Sell
317,476
-220,482
-41% -$6.76M 1.78% 19
2022
Q2 		$14.5M Hold
537,958
– – 2.64% 7
2022
Q1 		$18.3M Buy
537,958
+118,742
+28% +$3.8M 2.41% 11
2021
Q4 		$16.2M Buy
419,216
+148,785
+55% +$6.48M 2.41% 9
2021
Q3 		$14.6M Sell
270,431
-95,113
-26% -$4.46M 1.03% 21
2021
Q2 		$12.2M Sell
365,544
-230,746
-39% -$6.33M 0.99% 26
2021
Q1 		$12.3M Sell
596,290
-768,700
-56% -$17.7M 0.41% 55
2020
Q4 		$23.9M Sell
1,364,990
-104,740
-7% -$1.89M 1.05% 17
2020
Q3 		$21.8M Sell
1,469,730
-177,709
-11% -$2.08M 1.58% 14
2020
Q2 		$21.4M Buy
+1,647,439
New +$7.3M 1.7% 11

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Ikarian Capital's CLDX Position: Q1 2026 in Review

Ikarian Capital opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 461,247 shares worth $14.6M. The stake represents 1.19% of the portfolio and ranks #21 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in CLDX as recently as Q1 2023.

Ikarian Capital first reported a position in CLDX in Q2 2020 and has held it in 13 quarters since. The position peaked at $23.9M in Q4 2020. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Ikarian Capital held 461,247 shares of Celldex Therapeutics worth $14.6M as of Q1 2026.
  • Celldex Therapeutics was a new Ikarian Capital position in Q1 2026.
  • Celldex Therapeutics made up 1.19% of Ikarian Capital's portfolio in Q1 2026, its #21 holding.
  • Ikarian Capital first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • Ikarian Capital's Celldex Therapeutics position peaked at $23.9M in Q4 2020.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.